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Abstract
Background: The aim of current study is to verify usefulness of staging laparoscopy (stag-lap) for patient’s selection
and to find prognostic factors in patients with radiographically defined locally advanced (RD-LA) pancreatic ductal
adenocarcinoma (PDAC).
Methods: The LA disease was defined as an unresectable disease without distant organ metastasis based on
resectability status of NCCN guideline in this study. Stag-lap was performed in 67 patients with RD-LA (2007–2012)
which were divided into 4 groups according to metastatic site: group CY (peritoneal fluid or washing cytology
positive and without any distant organ metastasis); group P (peritoneal dissemination); group L (liver metastasis);
group LA (peritoneal fluid or washing cytology negative and without any distant organ metastasis). Clinical
backgrounds, survival curves, and prognostic factors were investigated.
Results: There were 16 patients in CY group (24 %), 13 patients in P group (19 %), 10 patients in L group (15 %),
and 28 patients in LA group (42 %). Median survival time was 13 months in CY group and 11 months in LA group,
which was significantly better than 7 months in P group, respectively (p < 0.05). The rate of emergence of ascites in LA
was significantly better than in CY or P groups (p < 0.05). Multivariate analysis showed that the presence of partial
response and administration of second-line chemotherapy were significantly independent prognostic factors.
Conclusions: The majority of PDAC patients with RD-LA had occult distant organ metastasis. Clinical features and
survival curves were different depending on the site of occult distant organ metastasis. Administration of second-line
chemotherapy and responsiveness to chemotherapy were associated with favorable prognosis. Staging laparoscopy
should be routinely performed in patients with RD-LA PDAC (UMIN000019936).
Keywords: Staging laparoscopy, Peritoneal carcinomatosis, Occult distant organ metastasis, Second-line chemotherapy,
Locally advanced PDAC
Background
Pancreatic ductal adenocarcinoma (PDAC) is a lethal
disease with poor prognosis, even in patients who have
undergone resection with curative intent [1]. At the time
of diagnosis, the majority of patients have unresectable
disease with or without distant organ metastasis on im-
aging modality [1, 2]. Despite the advances and resolution
improvement of imaging technologies, less-invasive sta-
ging modalities are still limited in their ability to identify
accurately metastatic disease of small volume, resulting in
inappropriate patient selection for therapy [3].
Staging laparoscopy is a minimally invasive procedure
that can identify occult distant metastases, resulting in
appropriate patient selection for chemotherapy or che-
moradiation therapy [3]. Stefanidis et al. [4] stated in
their review that staging laparoscopy has an important
role in the staging algorithm of PDAC patients and will
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likely continue to be a valuable tool. Diagnostic lapar-
oscopy guidelines [5] have proposed that staging lapar-
oscopy should be considered after high-quality imaging
studies have excluded metastatic disease in appropri-
ately selected patients with locally advanced pancreatic
adenocarcinoma.
We had some clinical questions on the diagnoses and
clinical courses in radiographically defined locally ad-
vanced (RD-LA) patients, such as the frequency of occult
distant organ metastasis, the survival difference according
to the occult distant organ metastatic site, and the prog-
nostic factors in this patient population. Therefore, since
2007, we have introduced staging laparoscopy in PDAC
patients with RD-LA for further exploration of minute
distant organ metastases which were not detected by con-
ventional staging modalities [3]. In the current study, we
retrospectively assessed the rate of minute distant organ
metastasis in PDAC patients with RD-LA, compared the
clinical background and survival rate according to meta-
static site, and analyzed the prognostic factors.
Methods
A retrospective study was conducted using a prospective
database. A total of 70 out of 395 patients with PDAC
(267 unresectable and 128 resected) presented with
RD-LA between January 2007 and December 2012 at
Kansai Medical University Hospital, Osaka, Japan. Three
patients refused to undergo staging laparoscopy and there-
fore, ultimately, staging laparoscopy was performed in 67
patients with RD-LA. The LA disease was defined as an
unresectable disease without distant organ metastasis
based on resectability status of NCCN guideline [6] in this
study as follows; greater than 180° superior mesenteric ar-
tery encasement and any celiac abutment for pancreatic
head PDAC; superior mesenteric artery or celiac encase-
ment greater than 180° for pancreatic body and tail PDAC;
unreconstructible superior mesenteric/portal vein occlu-
sion and aortic invasion or encasement for both PDAC.
These 67 patients were divided into 4 groups according to
metastatic site; group CY (cytology positive and without
any distant organ metastasis); group P (peritoneal dissem-
ination); group L (liver metastasis); group LA (pure locally
advanced disease, without positive cytology and any dis-
tant organ metastasis). Clinical backgrounds and survival
curves according to metastatic site were compared among
groups and investigated as a prognostic factor for this
population. All patients were followed up for at least
1 year.
All patients had a pathological evidence of PDAC before
or during staging laparoscopy. Resectability was assessed
with cine-imaging MDCT, using the Aquilion® CT system
(Toshiba Medical Systems, Tochigi, Japan). Arterial- and
portal-phase images were collected using a 1.0 × 64 mm
detector configuration. After reconstruction of the raw
scans, data from serial 1.0-mm-thick slices with a 0.5-mm
interval were transferred to a workstation (AquariusNet
Viewer, TeraRecon Inc., San Mateo, CA, USA). After
creating two- and three-dimensional coronal and sagittal
anatomical reconstructions, the cine images were evaluated
by an experienced hepatopancreatobiliary surgeon and a
consultant radiologist. The clinical response rate was based
on the Response Evaluation Criteria in Solid Tumors
(RECIST) [7], and partial response was defined as at least a
30 % decrease in the sum of diameters of target lesions,
taking as reference the baseline sum diameters.
Patients with resectable, borderline resectable, and
metastatic PDAC based on cine-imaging MDCT were ex-
cluded from the study. Patients with cancer of the pancre-
atic body and tail, with celiac trunk invasion, but with no
invasion of the superior mesenteric and pancreaticoduo-
denal arteries, were also classified as potential candidates
for resection with curative intent in this institution and
thus excluded from participation. Positron emission
tomography (PET) scanning was performed in patients
with suspicion of metastatic disease in the lung, cervical, or
para-aortic lymph nodes on cine-imaging MDCT. All pa-
tients with a suspicion of distant organ metastasis diag-
nosed by PET scanning were excluded after confirmation
of adenocarcinoma in the biopsy specimens from locations
such as the liver, lung, cervical lymph nodes, and bone. Al-
though the patients with omental cake or multiple periton-
eal nodules greater than 10-mm diameter were also
excluded from the study, patients with suspicion of peri-
toneal metastasis less than 10-mm diameter on MDCT or
ascites limited to the Pouch of Douglas were recruited.
The location of the metastatic site diagnosed by the
staging laparoscopy was recorded. Patients with occult
distant organ metastasis were treated with gemcitabine
or S-1-based chemotherapy or combination chemotherapy
of gemcitabine and S-1. Radiation therapy was added as
the first-line treatment concomitant with chemotherapy in
15/28 patients with locally advanced tumor or 5/16 pa-
tients with positive cytology. Second-line chemotherapy
(gemcitabine, S-1, or gemcitabine and S-1) was adminis-
tered to patients with their consent and if they also had a
good performance status. The time of development of as-
cites according to the site of distant organ metastasis was
also recorded.
Informed consent was obtained from each patient in-
cluded in the study, in accordance with the provisions of
the Declaration of Helsinki. Patient data were obtained
from the prospective database of pancreatic disease at
Kansai Medical University Hospital.
Staging laparoscopy
Briefly, after establishing the pneumoperitoneum through
a 12-mm trocar inserted at the umbilical area, a flexible
laparoscope was inserted and two additional 5-mm ports
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were placed. First, an inspection focusing on the presence
or absence of nodules on the parietal peritoneum and the
liver surface was carefully performed. Second, a cytological
examination was performed in cases where ascites was
present. When there was no ascitic fluid, the peritoneal
cavity was washed with 100 ml of physiologic saline solu-
tion. After placing the patient in Trendelenburg’s position,
the presence or absence of nodules in the Pouch of
Douglas was checked by inserting the laparoscope through
filled water into the Pouch of Douglas. Subsequently, cyto-
logic washings from the Pouch of Douglas were obtained
for pathological examination. Third, the entire mesentery
was examined by grasping the small intestine from the
first jejunal loop to the ileocecal junction to locate the mi-
nute peritoneal nodules. Biopsies were taken from any re-
gions suspected of containing metastatic nodules. Neither
the lesser nor the greater sac was opened in this study.
This clinical study was registered as UMIN000019936.
Statistical analysis
Data are expressed as median values and ranges. Clinical
background and clinical course were compared according
to metastatic site in Table 1. Continuous or categorical
variables were compared by Mann–Whitney U test, chi-
square test, or Fisher’s exact test as appropriate. Overall
survival curve, defined as the time from initial treatments
to death or the last follow-up date, were compared using
the log-rank test according to metastatic site. In addition,
profound factors identified by the univariate analysis were
further examined by multivariate Cox proportional-hazard
models to determine independent significant factors for
survival. The hazard ratio and 95 % confidence intervals
were calculated for all estimates. A two-tailed p value less
than 0.05 was considered to be statistically significant.
Statistical analyses were performed using SPSS version
18.0 for Windows (Chicago, IL, USA).
Results
Outcome measures of staging laparoscopy
Median operative time was 67 min (34–168) and median
extent of blood loss was 0 ml (0–168). Past history of
previous surgery was found in 12 out of 67 patients
(18 %). Three patients needed open mini-laparotomy
converted from staging laparoscopy because of severe
adhesion due to previous surgeries. Biopsy specimens
were obtained from 43 patients (64 %) for evaluating if
Table 1 Patient characteristics and clinical course in each group
Parameters LA (n = 28) CY (n = 16) P (n = 13) L (n = 10)
Gender (M/F) 14:14 11:5 6:7 6:4
Age (years) 66 (47–82) 63 (41–85) 69 (42–78) 63 (55–75)
PS 0/1 vs 2 26:2 16:0 12:1 8:2
Location (Pbt/Ph) 11:17 (39) 6:10 (38) 10:3 (77) 6:4 (60)
Tumor size (mm) 41 (23–76) 41 (27–91) 47 (21–88) 37 (28–85)
Size > 39.5 vs low 15:13 9:7 9:4 3:7
DM (yes/no) 5:23 3:13 5:8 4:6
Obstructive jaundice (yes/no) 15:13 7:9 4:9 5:5
Bilirubin (mg/dl) 0.8 (0.3–10) 0.7 (0.4–2.8) 0.6 (0.4–1.3) 0.9 (0.5–1.8)
Albumin (g/l) 3.6 (2.3–4.5) 3.8 (2.9–4.6) 4.0 (2.7–4.6) 4.0 (3.3–4.7)
Hemoglobin (g/dl) 11.7 (8–14.7) 11.9 (10.5–14.9) 12.4 (10.2–14.8) 13.3 (11–14.9)
CA19-9 (IU/l) 232 (1–3978) 371 (18–13,400) 385 (6–18,977) 997 (66–34,408)
CTx vs BSC 23:5 16:0 9:4 9:1
Duration of CTx (months) 7.5 (0–64) 10 (1.5–53) 3 (0–10) 6 (0–17)
GS (yes/no) 12:16 7:9 2:11 3:7
Radiation (yes/no) 15:13 5:11 0:13 0:10
Second-line chemotherapy (yes/no) 18:10 10:6 1:12 7:3
CR/PR vs SD/PD 9:19 6:10 2:11 2:8
1-year survival rate 50 % 63 % 31 % 20 %
Adjuvant surgery 1/28 2/16 0 0
Development of ascites within 1 year 10/28 (36 %) 7/16 (44 %) 11/13 (85 %) 5/10 (50 %)
Data are expressed as the median (range) or n (%)
LA locally advanced, CY positive cytology, P peritoneal metastasis, L liver metastasis, M male, F female, PS performance status, Ph pancreas head, Pbt pancreas
body and tail, DM diabetes mellitus, CA19-9 carbohydrate antigen 19-9, CTx chemotherapy, BSC best supportive care, GS gemcitabine and S-1, CR complete response,
PR partial response, SD stable disease, PD progressive disease
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occult distant organ metastasis was present. One patient
incidentally had intestinal perforation during staging lapar-
oscopy, and primary closure was immediately done.
Her postoperative course was uneventful and underwent
chemotherapy without delay.
Exploration using staging laparoscopy clearly demon-
strated the presence of occult distant organ metastasis in
39 out of 67 patients (58 %). There was positive cytology in
16 patients (CY, 24 %), peritoneal dissemination in 13 pa-
tients (P, 19 %), liver metastasis only or concomitant with
peritoneal metastasis in 10 patients (L including 3 patients
with concomitant peritoneal metastasis, 15 %), and locally
advanced disease in 28 patients (LA, 42 %), respectively.
Comparison of clinical backgrounds and clinical course
according to metastatic site
With regard to the clinical backgrounds and the clinical
course, as shown in Table 1, the L or P groups had a
higher frequency of pancreatic body and tail cancer, com-
pared with the LA or CY groups. Addition of radiation
therapy during chemotherapy was frequently performed
in the LA and CY groups according to the departmental
policy. The clinical response rate, as based on the RECIST
[7], was higher in the LA or CY groups than in either the
P or L groups. When the rate of emergence of ascites
according to the site of occult distant organ metastasis
was compared, it was significantly lower in the LA
group than in CY or P group (Fig. 1, p < 0.05). Develop-
ment of ascites within 1 year after initial treatment was
found most frequently in patients in the P group (11 out
of 13 patients, 85 %), which was higher than in the other 3
groups. Second-line chemotherapy was administered less
frequently in P group (1 out of 13 patients, 8 %), relative
to the other three groups (Table 1). Moreover, duration of
chemotherapy in P group was shorter than in the other
groups.
Patient at risk (%) 1y 2y 3y
LA n=28 11 3 1
CY n=16 5 1 0 
P    n=13 0 0 0











Month after staging laparoscopy
Fig. 1 The rate of emergence of ascites according to metastatic site diagnosed by staging laparoscopy. Figure 1 shows the curve of emergence
of ascites in patients with locally advanced PDAC (LA, solid black line), with positive cytology (CY, solid grey line), with peritoneal metastasis (P, dotted
grey line), and with liver metastasis (L, dotted black line). There were significant differences in the rate of emergence of ascites between LA and
P (p < 0.001) and LA and CY (p = 0.033) groups
Satoi et al. World Journal of Surgical Oncology  (2016) 14:14 Page 4 of 8
Median survival time was 13 months in the CY group
(including 2 patients who underwent surgical resection),
11 months in the LA group (including 1 patient who
underwent surgical resection), and 7 months in the P
and L groups, respectively. Actual 1-year survival rates
in the 4 groups were as follows: 46 % (LA), 63 % (CY),
23 % (P), and 20 % (L). No patient in the P and L groups
was alive beyond the 2-year follow-up. Thus, as shown
in Fig. 2a, the overall survival curve in P group was
significantly worse than in either the LA or CY groups
(p = 0.04 and p = 0.007, respectively). No significant
differences in the survival curves were seen between
CY and LA, P and L, or LA and L groups. As shown in
Fig. 2b, the survival curve in the LA + CY groups was
significantly better than in the P + L groups (p = 0.011).
In the LA or CY groups, additional radiation therapy
was administered to approximately 30–50 % of patients,
PR according to RECIST [7] was observed in approxi-
mately 35 % of patients, and second-line chemotherapy
was administered to around 60 % of patients. In this study,
out of 44 patients in LA and CY groups, conversion
surgery was performed in two patients in the CY group
(one alive after 60 months; the other died at 18 months,
respectively) and one patient in the LA group (alive after
17 months). The multivariate analysis showed that the
presence of partial response and administration of second-
line chemotherapy were significantly independent favorable
factors for prognosis (Table 2).
Discussion
The majority of patients with PDAC have unresectable
disease at initial presentation, and their prognosis is ex-
tremely poor. The median survival time of these patients
ranges from 6 to 12 months in spite of developed, ad-
vanced, and newly provided regimens of chemotherapy
[8–11]. Accurate staging is necessary for selecting pa-
tients who should be curatively resected, for introducing
new regimens of chemotherapy or chemo(radio)therapy,
or for conducting a clinical trial. Several articles have
reported that the use of staging laparoscopy to further
explore locally advanced PDAC, initially diagnosed by
CT scan, has identified the presence of occult distant
organ metastasis [4, 5, 12–17]. However, less informa-
tion is available on clinical background and clinical
course according to occult distant metastatic site
diagnosed by staging laparoscopy in patients with
RD-LA PDAC. Understanding the clinical features
according to the site of occult distant organ metastasis is
important for the development of new strategies and
improving prognosis in patients with locally advanced
PDAC.
We have focused on RD-LA PDAC defined by the
NCCN guidelines [6], excluding resectable, borderline
resectable, and metastatic diseases. The results of staging
laparoscopy in this study showed occult distant organ
metastasis in 58 % of patients including positive cytology
in 24 %, peritoneal dissemination in 19 %, and liver
Patient at risk (%) 1y 2y 3y MST
LA n=28 13 3 1 11
CY n=16 10 1 1 13
P    n=13 3 0 0 7.0
Liver n=10 2 0 0 7.0
Month after staging laparoscopy
Patient at risk (%) 1y 2y 3y
LA+CY n=44 23 4 2











Month after staging laparoscopy
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Fig. 2 Survival curves according to metastatic site diagnosed by staging laparoscopy. a shows survival curve of patients with locally advanced
PDAC (LA, solid black line), with positive cytology (CY, solid grey line), with peritoneal metastasis (P, dotted grey line), and with liver metastasis (L, dotted
black line). There were significant differences between the survival curves of P and CY (p = 0.007) and P and LA (p = 0.04) groups. b shows survival
curves of patients with locally advanced PDAC and positive cytology (LA + CY, solid black line) and with peritoneal metastasis and liver
metastasis (P + L, dotted black line). The survival curve in LA + CY groups was significantly better than in P + L groups (p = 0.011)
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metastasis in 15 %, respectively. Finally, pure locally ad-
vanced disease without minute distant organ metastasis
was found in 42 % of patients only. Clark et al. [12] re-
ported that diagnostic laparoscopy for borderline resectable
and unresectable locally advanced diseases showed occult
distant organ metastasis in 58 of 202 patients (29 %) in-
cluding positive peritoneal lavage cytology in 20 % (n = 41),
liver metastasis in 13 % (n = 26), and peritoneal metastases
in 3 % (n = 5) (Table 3). Relative to Clark et al. [12], our
study consisted of a more limited population of unresect-
able, locally advanced PDAC. As shown in Table 3, com-
pared with other studies, our study consisted of high
frequency of pancreatic body and tail cancer, which was as-
sociated with unresectability and the presence of occult
distant organ metastasis [4, 5]. In our experience, we had
an aggressive attitude towards surgical resection, even
in patients with portal or superior mesenteric vein inva-
sion, common hepatic artery invasion, and celiac axis
invasion for pancreatic body cancer. The definition of
local unresectability for our patients was strictly limited.
Moreover, we also recruited patients with suspicion of peri-
toneal metastasis less than 10-mm diameter on MDCT or
ascites limited to the Pouch of Douglas. Therefore, this
could explain why a high incidence of occult distant organ
metastasis (58 %) and peritoneal metastasis (19 %) was
found in our study.
We have introduced palliative chemotherapy in patients
with distant organ metastasis including peritoneal
metastasis, and chemo(radio)therapy for tumor remission
in patients with LA or CY. The clinical findings by staging
laparoscopy can provide to change the paradigm of the
treatment in patients with RD-LA PDAC. Actually,
peritoneal and/or liver metastasis was observed in
34 % of patients, who were treated with palliative
chemotherapy. Thus, the results of staging laparos-
copy changed the treatment according to distant
organ metastatic sites. Considering the high frequency
of patients with occult distant organ metastasis, staging
laparoscopy should be routinely performed in patients
with RD-LA PDAC.
With regard to the comparison of survival curves ac-
cording to the site of occult distant organ metastasis, P or
L groups had a worse prognosis than either the CY or LA
groups in our study. Actual 1-year survival rate was 46 %
in LA, 63 % in CY, 23 % in P, and 20 % in L groups. In the
LA or CY groups, high frequency of additional radiation,
PR according to RECIST, second-line chemotherapy and
conversion surgery might result in better prognosis.
Appearance of partial or complete response after chemo
(radio)therapy can sometimes lead to subsequent surgical
resection. It has been reported that the overall survival
rate in patients with initially unresectable PDAC who
underwent surgical resection after favorable response to
anti-cancer treatments over a period of time was similar
to that in patients with resectable PDAC [18, 19]. Even in
patients with initially unresectable disease, long-term
Table 2 Uni- and multivariate analyses for prognosis
Variable Univariate analysis Multivariate analysis
p Hazard ratio (95 % CI) Estimate SE p Hazard ratio (95 % CI))
CR/PR vs SD/PD <0.001 0.23 (0.12–0.45) −1.30 0.37 <0.001 0.27 (0.13–0.56)
Second-line chemotherapy none vs done <0.001 3.60 (2.03–6.37) 0.98 0.40 0.013 2.67 (1.23–5.78)
GS none vs done 0.009 2.05 (1.19–3.52) 0.21 0.34 0.53 1.24 (0.64–2.39)
Radiation none vs done 0.009 2.21 (1.22–4.01) 0.13 0.39 0.73 1.14 (0.53–2.45)
No ascites vs development of ascites at 1 year <0.001 0.39 (0.23–0.65) −0.12 0.31 0.70 0.89 (0.48–1.63)
LA/CY vs P/L 0.015 0.51 (0.30–0.88) −0.11 0.32 0.72 0.89 (0.48–1.68)
CI confidential interval, SE standard and error, CR complete response, PR partial response, SD stable disease, PD progressive disease, GS gemcitabine and S-1,
LA locally advanced, CY positive cytology, P peritoneal metastasis, L liver metastasis, CTx chemotherapy, BSC best supportive care
Table 3 Review of the recently published articles on staging laparoscopy in patients with locally advanced pancreatic cancer




Laparoscopic findings (%) MST(months)
True LA Occult met CY P Liver P/Liver
Clark et al. [12] 2010 00–08 202 22 % 144 (71 %) 58 (29) 41 (20) 5 (3) 26 (13) - 13
Morak et al. [13] 2009 95–07 68 - 44 (65) 24 (35) 14 (21) 5 (7) 2 (3) 11.7
Contreras et al. [14] 2009 02–06 33 15 % 22 (67) 11 (33) - 7 (21) 4 (12)
Shoup et al. [15] 2004 94–00 100 31 % 63 (63) 37 (37) 12 (12) 18 (18) 7 (7) -
Current study - 07–12 67 51 % 28 (42) 39 (58) 16 (24) 13 (19) 7 (10) 3 (4) 10
Pts patients, LA locally advanced, met metastasis, CY positive cytology, P peritoneal metastasis, MST median survival time
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survival can be expected if an unresectable tumor was
surgically resected after tumor shrinkage. Advanced
chemotherapy or chemoradiation therapy may have a
role in downsizing an unresectable tumor sufficiently to
render it resectable. Thus, a new strategy to shrink the
tumor in LA or CY group should be introduced where
possible to allow for subsequent surgical resection, which
is associated with long-term survival.
The multivariate analysis showed that the presence of
partial response and administration of second-line chemo-
therapy were significantly independent favorable factors
for prognosis (Table 2). The curve of emergence of ascites
in CY or P group was significantly worse than in LA
group (Fig. 1, p < 0.05). The P group in particular had asci-
tes in 85 % of patients within 1 year after initial treatment.
Moreover, no patient survived longer than 2 years after
initial treatment in P group. A lower frequency of second-
line chemotherapy and clinical response and shorter dur-
ation of chemotherapy in P group were found in this
study, probably due to emergence of ascites and poor per-
formance status. Thus, conventional chemotherapy may
not be effective for patients with peritoneal metastasis,
and therefore, a new regimen to control or prevent ascites
will be required for achieving better prognosis. In this
regard, intraperitoneal chemotherapy may be one op-
tion for patients with peritoneal metastasis that should
be investigated. A Japanese case report described the
success of intraperitoneal paclitaxel combined with
systemic chemotherapy of S-l and gemcitabine for locally
advanced PDAC with peritoneal carcinomatosis [20].
After 20 months, all peritoneal deposits had disappeared
and a radical resection of the tumor was performed.
Sugarbaker et al. [21] have conducted a phase II study of
hyperthermic intraoperative gemcitabine and long-term
intraperitoneal gemcitabine in the adjuvant setting for
resectable PDAC patients. Further protocol-based studies
should be performed to investigate whether prognosis
in patients with occult peritoneal metastasis can be
improved or not.
The limitation of the study was the small number of
patients recruited retrospectively and the presence of
undetectable liver metastasis deep within the liver and/or
other organ metastasis.
Conclusions
In conclusion, staging laparoscopy is necessary for
selecting patients with occult distant organ metastasis
which is the majority population of patients with RD-LA
PDAC. Clinical features and survival curves were different
depending on the site of occult distant organ metastasis.
Administration of second-line chemotherapy and respon-
siveness to chemotherapy were associated with favorable
prognosis. Staging laparoscopy should be routinely per-
formed in PDAC patients with RD-LA.
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